Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael J. Hitchcock
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Beta
- -0.30
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- -17.91
Financials
Net Income
$-8.33MEBITDA
$-8.31MFree Cash Flow
$-10.03MEPS (diluted)
$-0.12Shares Outstanding (diluted)
72.36M+575.8%Operating Expenses
$12.77MCash & Debt
$34.82MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-61.80M | $-1.18 |
| 2024 | $0.00 | $-138.43M | $-3.83 |
| 2023 | $0.00 | $-117.25M | $-3.44 |
| 2022 | $0.00 | $-81.83M | $-2.80 |
| 2021 | $0.00 | $-41.57M | $-1.74 |
| 2020 | $0.00 | $-5.32M | $-0.50 |
| 2019 | $0.00 | $-1.20M | $-0.11 |
Valuation
BMEAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-48.78%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·15d ago·Positive
…Termination of Proposed Public Offering of Securities SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously announced on September 22, 2026. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that wou…
View source ↗ - Newsglobenewswire.com·15d ago·Neutral
Biomea Fusion Announces Proposed Public Offering of Securities SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purch…
View source ↗ - Newszacks.com·33d ago·Neutral
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright Biomea Fusion, Inc. (BMEA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BMEA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
… in Upcoming Investor Conferences SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.
View source ↗ - Newsbenzinga.com·44d ago·Negative
Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion Shares of Biomea Fusion Inc (NASDAQ:BMEA) are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
… in Insulin-Deficient Type 2 Diabetes SAN CARLOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II clinical trial evaluating icovamenib in patients with insulin-deficient T2D who remain inadequately controlled on standard-of-care antihyperglycemic t…
View source ↗ - Newsinvezz.com·45d ago·Neutral
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it? Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying about 410% upside from the price used in Citi's call, while his $57 Syndax Pharmaceuticals target points to roughly 190%.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.21 per share
Typical surprise +13.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.12 vs $-0.22beat
- Mon, May 11$-0.17 vs $-0.24beat
- Tue, Mar 24$-0.64 vs $-0.25miss
- Tue, Nov 4$-0.27 vs $-0.26miss
- Tue, Aug 5$-0.51 vs $-0.59beat
- Mon, May 5$-0.80 vs $-0.84beat
Estimates and results for BMEA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BMEA officers and directors.
- Bought
- $12.9m
- Sold
- $32.8m
12 trades
10 trades
- Erdtmann Rainer Mbought
- Hitchcock Michael J.m.bought
- Erdtmann Rainer Mbought
- Erdtmann Rainer Mbought
- Hitchcock Michael J.m.bought
- Valle Francobought
- A2a Pharmaceuticals, Inc.sold
- A2a Pharmaceuticals, Inc.sold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BMEA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.